These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29793436)

  • 1. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.
    Ruzicka DJ; Tetsuka J; Fujimoto G; Kanto T
    BMC Infect Dis; 2018 May; 18(1):237. PubMed ID: 29793436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: A hospital claims database study.
    Ruzicka DJ; Imai K; Takahashi K; Naito T
    J Infect Chemother; 2019 Feb; 25(2):89-95. PubMed ID: 30396821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.
    Lauffenburger JC; Mayer CL; Hawke RL; Brouwer KL; Fried MW; Farley JF
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1073-82. PubMed ID: 25014625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database.
    Ruzicka DJ; Imai K; Takahashi K; Naito T
    BMJ Open; 2018 Jun; 8(6):e019985. PubMed ID: 29903786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis].
    Wang Q; Rao HY; Yu N; Gao SQ; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):225-232. PubMed ID: 29804396
    [No Abstract]   [Full Text] [Related]  

  • 7. Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.
    Chung JW; Choi HY; Ki M; Jang ES; Jeong SH
    Gut Liver; 2021 Mar; 15(2):295-306. PubMed ID: 32616682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.
    Naito T; Suzuki M; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Fujibayashi K; Goto-Hirano K; Kuwatsuru R
    HIV Med; 2022 May; 23(5):485-493. PubMed ID: 34821006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
    Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
    Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
    Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    Hudson B; Walker AJ; Irving WL
    J Med Virol; 2017 Dec; 89(12):2158-2164. PubMed ID: 28480974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    Evon DM; Stewart PW; Amador J; Serper M; Lok AS; Sterling RK; Sarkar S; Golin CE; Reeve BB; Nelson DR; Reau N; Lim JK; Reddy KR; Di Bisceglie AM; Fried MW
    PLoS One; 2018; 13(8):e0196908. PubMed ID: 30067745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study.
    Bourgeois S; Mulkay JP; Cool M; Verhelst X; Robaeys G; Lasser L; Lefebvre V; Colle I; Van Steenkiste C; Decaestecker J; Coulon S; Venken K; Vanwolleghem T
    Acta Gastroenterol Belg; 2021; 84(1):33-41. PubMed ID: 33639691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high comorbidity burden of the hepatitis C virus infected population in the United States.
    Louie KS; St Laurent S; Forssen UM; Mundy LM; Pimenta JM
    BMC Infect Dis; 2012 Apr; 12():86. PubMed ID: 22494445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients.
    Abd Elaziz MS; Nada ASE; ElSayed SH; Nasr GS; Zaky AG
    Int Ophthalmol; 2020 May; 40(5):1245-1251. PubMed ID: 31965393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data.
    Silvestri C; Bartolacci S; Pepe P; Monnini M; Voller F; Cipriani F; Stasi C
    World J Gastroenterol; 2016 Nov; 22(44):9829-9835. PubMed ID: 27956807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
    Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
    Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain.
    Sicras-Mainar A; Navarro-Artieda R; Sáez-Zafra M
    Gastroenterol Hepatol; 2018 Apr; 41(4):234-244. PubMed ID: 29287992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.